Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the
Summit Therapeutics showed that their new lung cancer medicine helped patients live longer. The good results stayed strong across different countries, which is a healthy sign.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.